TELO
Telomir·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 0
Ample Liquidity
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About TELO
Telomir Pharmaceuticals, Inc.
A preclinical stage biotechnology company
100 SE 2nd St, Suite 200 #1009, Miami, Florida 33131
--
Telomir Pharmaceuticals, Inc., was incorporated as a Florida company in August 2021. The company is a preclinical stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule under development for oral in situ therapeutic therapy of human stem cells. In situ stem cell therapy uses the body's natural resources to regenerate damaged tissue and replace cells with new functional cells.
Company Financials
EPS
TELO has released its 2025 Q3 earnings. EPS was reported at -0.03, versus the expected -0.07, beating expectations. The chart below visualizes how TELO has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
